Differential NAD + availability may drive asymmetric SIRT7 activity in tumor and immune cells.

Metabolic competition within the tumor microenvironment shapes the availability of nutrients and metabolites that regulate both tumor progression and antitumor immunity. Among the molecules linking metabolism to gene regulation, the NAD + -dependent enzyme SIRT7 has emerged as an important regulator of ribosome biogenesis, genome stability, chromatin organization, and metabolic adaptation. Although SIRT7 is frequently associated with tumor progression, emerging evidence indicates that it also supports the metabolic fitness and effector functions of immune cells, suggesting that its biological consequences are highly cell type-dependent. However, the mechanisms underlying these apparently opposing functions remain poorly understood. A conceptual framework is presented in which differences in intracellular NAD + availability contribute to asymmetric SIRT7 activity in tumor and immune cells within the tumor microenvironment. Many tumor types preserve intracellular NAD + through metabolic rewiring, whereas infiltrating immune cells frequently experience sustained metabolic stress and progressive NAD + depletion owing to nutrient competition. Although direct evidence demonstrating that physiological fluctuations in intracellular NAD + regulate SIRT7 activity in vivo remains limited, biochemical studies indicate that SIRT7 displays a relatively high apparent Michaelis constant (Km) for NAD + compared with other mammalian sirtuins, providing a biochemical rationale for increased sensitivity to changes in intracellular NAD + availability. Current evidence from SIRT7 biology, cancer metabolism, and immunometabolism is integrated to evaluate this conceptual framework, identify key limitations in the available data, and highlight experimental questions that should be addressed to determine whether differential NAD + availability represents a fundamental mechanism underlying the context-dependent functions of SIRT7.